Publication Date
12-1-2025
Journal
ACR Open Rheumatology
DOI
10.1002/acr2.70132
PMID
41294283
PMCID
PMC12648625
PubMedCentral® Posted Date
11-26-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Objective: To determine the demographic and clinical characteristics associated with use of the EuroLupus or modified National Institutes of Health (NIH) cyclophosphamide (CYC) regimen for treatment of lupus nephritis (LN) at North American pediatric centers.
Methods: A retrospective cohort study was conducted at 11 North American centers. Patients < 22 years of age with active LN treated with CYC using the EuroLupus or NIH regimen between July 2014 and June 2021 were included. Data were extracted via electronic medical record review. Demographic and clinical characteristics were compared at CYC initiation. A multivariable generalized estimating equation with logit link was fit to model EuroLupus use. An exchangeable correlation structure was used to account for correlation within centers. Independent variables were chosen using elastic net regression.
Results: The cohort consisted of 191 patients (85 EuroLupus, 106 NIH) with a median age of 15.3 years at CYC initiation. In multivariable analysis, characteristics significantly associated with EuroLupus regimen use (vs NIH regimen use) included more recent year of CYC initiation, longer disease duration, Hispanic ethnicity and Asian race (as compared to Black), previous CYC treatment, renal impairment (dialysis or mild kidney impairment), and absence of neuropsychiatric involvement.
Conclusion: For children and young adults with LN requiring CYC, use of the EuroLupus regimen increased over time and is associated with demographic and clinical factors such as race or Hispanic ethnicity, renal impairment, and absence of neuropsychiatric involvement. The differences in regimen use with severe renal impairment and neuropsychiatric lupus highlight areas for future study in CYC dosing.
Published Open-Access
yes
Recommended Citation
Wang, Christine S; Sadun, Rebecca E; Zhou, Wenru; et al., "Characteristics Associated With EuroLupus Versus Modified National Institutes of Health Cyclophosphamide Regimen Use in Children and Young Adults With Lupus Nephritis" (2025). Faculty and Staff Publications. 5884.
https://digitalcommons.library.tmc.edu/baylor_docs/5884